155 related articles for article (PubMed ID: 37067635)
21. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
Bai Y; Niu D; Huang X; Jia L; Kang Q; Dou F; Ji X; Xue W; Liu Y; Li Z; Feng Q; Lin D; Kakudo K
Diagn Pathol; 2017 Oct; 12(1):72. PubMed ID: 28974264
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
23. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
24. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
[TBL] [Abstract][Full Text] [Related]
26. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Noh BJ; Kim JH; Eom DW
Ann Clin Lab Sci; 2018 Nov; 48(6):695-706. PubMed ID: 30610038
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
[TBL] [Abstract][Full Text] [Related]
30. Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma.
Kong SK; Kim BS; Lim H; Kim HJ; Kim YS
Lab Invest; 2022 Apr; 102(4):352-362. PubMed ID: 34789838
[TBL] [Abstract][Full Text] [Related]
31. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Mandarano M; Bellezza G; Belladonna ML; Van den Eynde BJ; Chiari R; Vannucci J; Mondanelli G; Ludovini V; Ferri I; Bianconi F; Del Sordo R; Cagini L; Albini E; Metro G; Puma F; Sidoni A
Virchows Arch; 2019 Feb; 474(2):159-168. PubMed ID: 30448912
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
33. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
35. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
Xu Y; Song G; Xie S; Jiang W; Chen X; Chu M; Hu X; Wang ZW
Mol Ther; 2021 Jun; 29(6):1958-1969. PubMed ID: 33932597
[TBL] [Abstract][Full Text] [Related]
36. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
[TBL] [Abstract][Full Text] [Related]
37. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.
Mathios D; Ruzevick J; Jackson CM; Xu H; Shah SR; Taube JM; Burger PC; McCarthy EF; Quinones-Hinojosa A; Pardoll DM; Lim M
J Neurooncol; 2015 Jan; 121(2):251-9. PubMed ID: 25349132
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells.
Lee JH; Lee DY; Lee HJ; Im E; Sim DY; Park JE; Park WY; Shim BS; Kim SH
Cells; 2021 Aug; 10(8):. PubMed ID: 34440920
[TBL] [Abstract][Full Text] [Related]
40. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]